

Information about proposed Board of Directors Annual General Meeting 2014

Proposal for re-election of the current members of the board of directors:

Adine Grate Axén

Born 1961.

Board member since 2010.

M.Sc. from Stockholm School of Economics, Harvard

AMP.

Other appointments: Board member of BSKyB Ltd, Sampo OY, HI3GS Holding AB, 3G, Infrastructure Services AB, HI3G Denmark ApS and Swedavia AB. Chairman of Nasdaq OMX Stockholm's Listing Committee and Vice Chairman of Sjunde AP-fonden.

Previous appointments: Member of the Commission for the sale of shares in companies with state ownership. Board member of Gambro AB, OMX AB 1994–2007, various senior management positions and Board assignments within Investor AB ; executive director and member of the management group 1999–2007. Board member of Acne Studios Holding AB, Evry AS, NASDAQ OMX and Carnegie Investment Bank AB.

Aktier: 32 000

Oberoende i förhållande till bolaget och bolagsledningen respektive större aktieägare i bolaget.

Matthew Gantz

Born 1965.

Board member since 2012.

BA Princeton University and MBA from Harvard Business School.

Other appointments: US Executive Vice President of BTG, an international specialist healthcare company.

Previous appointments: Founder and previously CEO of Acureon Pharmaceuticals, President and CEO of Hydrabiosciences Inc., Vice President Europe for Chiron's Biopharmaceutical Division and General Manager for Patho Genesis Europe. Prior to Chiron/PathoGenesis, a variety of US sales and marketing roles at Abbott Laboratories Diagnostic Division.

Shares: 0

Oberoende i förhållande till bolaget och bolagsledningen respektive större aktieägare i bolaget.

Bo Jesper Hansen

Born 1958.

Chairman and Board member since 2010.

M.D. with a Ph.D. from Copenhagen University.

Other appointments: Board member of HyperionTherapeutics Inc., GenSpera Inc., Topotarget A/S, Orphazyme ApS, Karolinska Development AB, and Ablynx NV.

Previous appointments: Various positions in Swedish Orphan International AB since 1993 including CEO from 1998–2010. Medical advisor for Synthélabo, Pfizer, Pharmacia and Yamanouchi. Founder of Scandinavian Medical Research.

Shares: 8,893,846

Beroende i förhållande till bolaget och bolagsledningen, men oberoende i förhållande till större aktieägare i bolaget.

Lennart Johansson

Born 1955.

Board member since 2010.

M.Sc. from Stockholm School of Economics.

Other appointments: Member of the management team and Head of Financial and Core Investments at Investor AB. Board member of Hi3G and Lindorff group.

Previous appointments: CEO in b-business partners and Emerging Technologies AB. Board member of SAAB AB, IBX Group AB, Gambro Holding AB and Mölnlycke Health Care.

Shares: 20,000

Oberoende i förhållande till bolaget och bolagsledningen, men beroende i förhållande till större aktieägare i bolaget.

Helena Saxon

Born 1970.

Board member since 2011.

M.Sc. from Stockholm School of Economics.

Other appointments: Investment Manager at Investor AB, Board member of Aleris and Mölnlycke Health Care.

Previous appointments: CFO of Hallvarsson & Halvarsson, Vice President at Investor AB and financial analyst at Goldman Sachs.

Shares: 15,500

Oberoende i förhållande till bolaget och bolagsledningen, men beroende i förhållande till större aktieägare i bolaget.

Hans GCP Schikan

Born 1958.

Board member since 2011.

Pharm.D, Utrecht University.

Other appointments: CEO of Prosensa, The Netherlands. Board member of Top Institute Pharma. Member of the Advisory Board of BioScience Park Leiden. Member of Core Team Dutch Top Sector Life Sciences & Health.

Previous appointments: Chairman of Dutch Association of the Innovative Pharmaceutical Industry, Nefarma. Various senior management positions within previous Organon and Genzyme.

Shares: 0

Oberoende i förhållande till bolaget och bolagsledningen respektive större aktieägare i bolaget.

Hans Wigzell

Born 1938.

Board member since 2005.

M.D,D.Sc., Professor of Immunology.

Other appointments: Chairman of Rhenman & Partners Asset Management AB. Board member of Karolinska Development, RaySearch Laboratories AB (publ), Valneva SE(publ), Sarepta Therapeutics Inc (publ) and AB Wigzellproduktion. Member of the Royal Swedish Academy of Sciences and the Royal Swedish Academy of Engineering Sciences.

Previous appointments: President of Karolinska Institutet. Board member of NeoDynamics AB, PROBI AB and Diamyd Medical AB.

Shares: 200,000

Oberoende i förhållande till bolaget och bolagsledningen respektive större aktieägare i bolaget.

Proposal for election of new member of the board of directors:**Annette Clancy**

Born 1954.

BSc Hons Pharmacology, from Bath University UK.

Other appointments: Chairman as well as Non-Executive Director of the Board in Genable Technologies. Ms. Clancy has over 30 years of experience in the Pharmaceutical/Biopharm Industry, working in a variety of functions (R&D, Commercial, Worldwide Business Development) in the US and UK. Senior European Advisor to the Biopharmaceutical Team of Frazier Healthcare Ventures, for whom she provides strategic advice on both new and existing investments

Previous appointments: Head of Transactions and Alliance Management at GlaxoSmithKline (GSK) where she was responsible for executing major transactions ranging from early drug discovery partnerships, to global commercial alliances and Mergers and Acquisitions.

Since her retirement from GSK in 2008, Ms. Clancy has been appointed as Non-Executive Board Director to Silence Therapeutics plc. (2008-2012) and Clavis Pharma in Norway (2010-2013).

Shares: 0

Annette Clancy is independent in relation to the company and its management and in relation to the company's principal shareholders.